Lineage Cell Therapeutics (LCTX) Research & Development (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Research & Development of $4.2 million for Q1 2026, up 35.97% year-over-year from $3.1 million in Q1 2025, and down 48.6% quarter-over-quarter from $8.2 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Research & Development (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.
- In Q1 2026, Research & Development rose 35.97% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $18.8 million (up 49.88% YoY), while the FY2025 annual figure was $17.7 million, up 42.15% from the prior year.
- Research & Development for Q1 2026 stood at $4.2 million, down from $8.2 million in the prior quarter.
- The five-year high for Research & Development was $8.2 million in Q4 2025, with the low at $2.9 million in Q2 2024.
- The 5-year median for Research & Development is $3.4 million (2024), against an average of $3.8 million.
- The sharpest annual moves came in 2022 and 2025: Research & Development tumbled 83.44% in 2022, then surged 140.67% in 2025.
- Lineage Cell Therapeutics' Research & Development stood at $4.1 million in 2022, then retreated by 4.82% to $3.9 million in 2023, then fell by 12.37% to $3.4 million in 2024, then soared by 140.67% to $8.2 million in 2025, then slumped by 48.6% to $4.2 million in 2026.
- Business Quant data shows LCTX's Research & Development at $4.2 million in Q1 2026, $8.2 million in Q4 2025, and $3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 4.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.77 Mn |
| Mar 31, 2026 | 4.23 Mn |
| Dec 31, 2025 | 8.24 Mn |
| Sep 30, 2025 | 3.27 Mn |
| Jun 30, 2025 | 3.11 Mn |
| Mar 31, 2025 | 3.11 Mn |
| Dec 31, 2024 | 3.42 Mn |
| Sep 30, 2024 | 3.17 Mn |
| Jun 30, 2024 | 2.87 Mn |
| Mar 31, 2024 | 3.01 Mn |
| Dec 31, 2023 | 3.91 Mn |
| Sep 30, 2023 | 3.74 Mn |
| Jun 30, 2023 | 3.87 Mn |
| Mar 31, 2023 | 4.19 Mn |
| Dec 31, 2022 | 4.10 Mn |
| Sep 30, 2022 | 3.59 Mn |
| Jun 30, 2022 | 3.30 Mn |
| Mar 31, 2022 | 2.99 Mn |
| Dec 31, 2021 | 24.78 Mn |
| Sep 30, 2021 | 2.81 Mn |